NCT04370483
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
StatusActive, Not Recruiting
PhaseEarly Phase 1
SponsorCity of Hope Medical Center
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Nov 10, 2026 to Oct 13, 2027
- Eligibility criteria expanded, about 21 words
- Secondary endpoints: details revised at 4 of 5 entries
- Notable Primary and study completion dates: Dec 16, 2025 to Nov 10, 2026v9
- Notable Primary and study completion dates: Dec 30, 2024 to Dec 16, 2025v8
- Notable Primary and study completion dates: Dec 30, 2023 to Dec 30, 2024v7
- Notable Primary and study completion dates: Jun 1, 2023 to Dec 30, 2023v6
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary and study completion dates: Jun 1, 2021 to Jun 1, 2023
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 10 to confirmed 1
- Site details revised
- Notable Start date changed from estimate of Jun 4, 2020 to Oct 8, 2020v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: May 1, 2020 to Jun 4, 2020
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progressive disease
Timeframe: Up to 48 months
Secondary (5)
Incidence of adverse events
Incidence of toxicities
Overall response rate
Overall survival
Quality of life Questionnaire
Arms and interventions
Treatment (leflunomide)Experimental
Patients receive leflunomide PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drugs: Leflunomide
Other: Quality-of-Life Assessment
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States